Drug intelligence / Profile preview

KBD151

Development stage: Preclinical
Lead developer: Baiyu Pharmaceutical
Modality: Small Molecules

Overview

KBD151 is an investigational small molecule drug candidate developed by Chengdu Baiyu Jingelai Pharmaceutical, a subsidiary of Chengdu Baiyu Pharmaceutical. It is currently being developed for the treatment of skin inflammation. As an early-stage asset in the company's innovative pipeline, its specific biological target and precise mechanism of action remain undisclosed. The drug is part of a broader effort by the developer to address inflammatory dermatological conditions using small molecule therapeutics.

Beyond the preview

Go deeper on KBD151.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KBD151.

Explore the full profile